{'fraction_non_alphanumeric': 0.04188948306595366, 'fraction_numerical': 0.017825311942959002, 'mean_word_length': 4.973404255319149, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Interferon-β1a in chronic inflammatory demyelinating polyneuropathy

Reported herein are the results of interferon-β1a (IFN-β1a) therapy in four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who failed to achieve a prolonged response to conventional therapy.

Patients. Three women and one man with a mean age of 57.25 years (range, 52 to 64 years) and a mean duration of symptoms of 8.3 years (range, 1.5 to 13 years) participated in the study. All had a sensorimotor polyneuropathy that fulfilled clinical and electrodiagnostic criteria for CIDP. None had monoclonal gammopathy. All had a relapsing or progressive course after treatment with prednisone, plasma exchange (PE), IV immunoglobulin (IVIg), azathioprine, or cyclophosphamide. All required cyclic therapy, but after their initial response they no longer improved. None had been treated with prednisone, PE, or IVIg for at least 8 weeks before starting IFN-β1a. During this period, no one reported clinical deterioration.

### Study design.

The study was planned to be a 6-month pilot, open-label therapeutic trial, with the right to …